Anixa Biosciences (ANIX) announced that the Canadian Intellectual Property Office, or CIPO, has issued a Notice of Allowance for a new patent related to its breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, will provide composition-of-matter protection for the Company’s novel immunogenic approach to breast cancer prevention and treatment in Canada. With this allowance, Anixa continues to expand the international scope of its intellectual property portfolio, reinforcing its leadership in the field of cancer immunoprevention. The Canadian patent complements issued and pending patents in the United States and other key global jurisdictions, and represents an important step toward future regulatory and commercial efforts outside the U.S.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Anixa Biosciences Receives Buy Rating Amidst Strong Patent Portfolio and Promising Vaccine Trials
- Anixa Biosciences awarded new U.S. patent for breast cancer technology
- Positive Outlook for Anixa Biosciences: Patent Secures Ovarian Cancer Vaccine and Promising CAR-T Therapy Progress
- Anixa announces issuance of additional USPTO for ovarian cancer vaccine tech
- Positive Outlook for Anixa Biosciences: Promising Cancer Treatment Trials Justify Buy Rating